An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: A proteomics approach

Free Radical Biology and Medicine

Volumn 76, Issue , 2014, Pages 89-95

  Cenini, Giovanna ^a   Fiorini, Ada ^a,c   Sultana, Rukhsana ^a   Perluigi, Marzia ^c   Cai, Jian ^d   Klein, Jon B ^d   Head, Elizabeth ^b   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d University of Louisville School of Medicine   (United States)

Author keywords

Alzheimer disease; Down syndrome; Free radicals; Neuropathology; Proteomics; Trisomy 21

Indexed keywords

ADOLESCENT; ADULT; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPHAGY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; ENERGY METABOLISM; FEMALE; FRONTAL CORTEX; HUMAN; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEOMICS; CASE CONTROL STUDY; CHILD; COMPARATIVE STUDY; COMPLICATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKER; PROTEOME;

ADOLESCENT; ALZHEIMER DISEASE; BIOMARKERS; CASE-CONTROL STUDIES; CHILD; CHROMATOGRAPHY, LIQUID; DOWN SYNDROME; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84907176725     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.08.006     Document Type: Article

References (66)

1. J. Lejeune Pathogenesis of mental deficiency in trisomy 21 Am. J. Med. Genet. Suppl. 7 1990 20 30
2. C.J. Epstein Developmental genetics Experientia 42 1986 1117 1128
3. D.M. Mann, and M.M. Esiri The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome J. Neurol. Sci. 89 1989 169 179
4. K. Wisniewski, J. Howe, D.G. Williams, and H.M. Wisniewski Precocious aging and dementia in patients with Down's syndrome Biol. Psychiatry 13 1978 619 627
5. F. Lai, and R.S. Williams A prospective study of Alzheimer disease in Down syndrome Arch. Neurol. 46 1989 849 853
6. J. Tyrrell, M. Cosgrave, M. McCarron, J. McPherson, J. Calvert, A. Kelly, M. McLaughlin, M. Gill, and B.A. Lawlor Dementia in people with Down's syndrome Int. J. Geriatr. Psychiatry 16 2001 1168 1174
7. A. Bush, and N. Beail Risk factors for dementia in people with Down syndrome: issues in assessment and diagnosis Am. J. Ment. Retard. 109 2004 83 97
8. D. Patterson Molecular genetic analysis of Down syndrome Hum. Genet. 126 2009 195 214
9. I. Das, and R.H. Reeves The use of mouse models to understand and improve cognitive deficits in Down syndrome Dis. Models Mech 4 2011 596 606
10. D.K. Lahiri, Y.W. Ge, B. Maloney, F. Wavrant-De Vrieze, and J. Hardy Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer's disease Neurobiol. Aging 26 2005 1329 1341
11. Y.H. Suh, and F. Checler Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease Pharmacol. Rev. 54 2002 469 525
12. I.T. Lott, and E. Head Down syndrome and Alzheimer's disease: a link between development and aging Ment. Retard. Dev. Disabil. Res. Rev 7 2001 172 178
13. C.A. Lemere, J.K. Blusztajn, H. Yamaguchi, T. Wisniewski, T.C. Saido, and D.J. Selkoe Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation Neurobiol. Dis. 3 1996 16 32
14. J.B. Leverenz, and M.A. Raskind Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis Exp. Neurol. 150 1998 296 304
15. S.V. Jovanovic, D. Clements, and K. MacLeod Biomarkers of oxidative stress are significantly elevated in Down syndrome Free Radic. Biol. Med. 25 1998 1044 1048
16. M. Perluigi, and D.A. Butterfield Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia Curr. Gerontol. Geriatr. Res 2012 2012 724904
17. M. Zana, Z. Janka, and J. Kalman Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease Neurobiol. Aging 28 2007 648 676
18. I.T. Lott, E. Head, E. Doran, and J. Busciglio Beta-amyloid, oxidative stress and Down syndrome Curr. Alzheimer Res. 3 2006 521 528
19. E. Head, W. Silverman, D. Patterson, and I.T. Lott Aging and Down syndrome Curr. Gerontol. Geriatr. Res 2012 2012 412536
20. N. Schupf, and G.H. Sergievsky Genetic and host factors for dementia in Down's syndrome Br. J. Psychiatry 180 2002 405 410
21. Y. Sun, M. Dierssen, N. Toran, D.D. Pollak, W.Q. Chen, and G. Lubec A gel-based proteomic method reveals several protein pathway abnormalities in fetal Down syndrome brain J. Proteomics 74 2011 547 557
22. M.S. Cheon, M. Fountoulakis, M. Dierssen, J.C. Ferreres, and G. Lubec Expression profiles of proteins in fetal brain with Down syndrome J. Neural Transm. Suppl. 61 2001 311 319
23. F. Di Domenico, G. Pupo, A. Tramutola, A. Giorgi, M.E. Schinina, R. Coccia, E. Head, D.A. Butterfield, and M. Perluigi Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease Free Radic. Biol. Med. 71C 2014 270 280
24. G. Cenini, A.L. Dowling, T.L. Beckett, E. Barone, C. Mancuso, M.P. Murphy, H. Levine 3rd, I.T. Lott, F.A. Schmitt, D.A. Butterfield, and E. Head Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome Biochim. Biophys. Acta 1822 2012 130 138
25. F. Di Domenico, R. Sultana, E. Barone, M. Perluigi, C. Cini, C. Mancuso, J. Cai, W.M. Pierce, and D.A. Butterfield Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects J. Proteomics 74 2011 1091 1103
26. D.A. Butterfield, and R. Sultana Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder J. Alzheimer's Dis 12 2007 61 72
27. M. Shi, W.M. Caudle, and J. Zhang Biomarker discovery in neurodegenerative diseases: a proteomic approach Neurobiol. Dis. 35 2009 157 164
28. S. Deutsch, R. Lyle, E.T. Dermitzakis, H. Attar, L. Subrahmanyan, C. Gehrig, L. Parand, M. Gagnebin, J. Rougemont, C.V. Jongeneel, and S.E. Antonarakis Gene expression variation and expression quantitative trait mapping of human chromosome 21 genes Hum. Mol. Genet 14 2005 3741 3749
29. M. Ling, F. Merante, H.S. Chen, C. Duff, A.M. Duncan, and B.H. Robinson The human mitochondrial elongation factor tu (EF-Tu) gene: cDNA sequence, genomic localization, genomic structure, and identification of a pseudogene Gene 197 1997 325 336
30. M. Freidl, T. Gulesserian, G. Lubec, M. Fountoulakis, and B. Lubec Deterioration of the transcriptional, splicing and elongation machinery in brain of fetal Down syndrome J. Neural Transm. Suppl. 61 2001 47 57
31. J.H. Shin, J. London, M. Le Pecheur, H. Hoger, D. Pollak, and G. Lubec Aberrant neuronal and mitochondrial proteins in hippocampus of transgenic mice overexpressing human Cu/Zn superoxide dismutase 1 Free Radic. Biol. Med. 37 2004 643 653
32. T. Reed, M. Perluigi, R. Sultana, W.M. Pierce, J.B. Klein, D.M. Turner, R. Coccia, W.R. Markesbery, and D.A. Butterfield Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease Neurobiol. Dis. 30 2008 107 120
33. D.A. Butterfield, J. Drake, C. Pocernich, and A. Castegna Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide Trends Mol. Med. 7 2001 548 554
34. S.G. Rhee, S.W. Kang, L.E. Netto, M.S. Seo, and E.R. Stadtman A family of novel peroxidases, peroxiredoxins BioFactors 10 1999 207 209
35. S.H. Kim, M. Fountoulakis, N. Cairns, and G. Lubec Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome J. Neural Transm. Suppl. 61 2001 223 235
36. F.V. Pallardo, P. Degan, M. d'Ischia, F.J. Kelly, A. Zatterale, R. Calzone, G. Castello, R. Fernandez-Delgado, C. Dunster, A. Lloret, P. Manini, M.A. Pisanti, E. Vuttariello, and G. Pagano Multiple evidence for an early age pro-oxidant state in Down syndrome patients Biogerontology 7 2006 211 220
37. H.F. Poon, H.M. Shepherd, T.T. Reed, V. Calabrese, A.M. Stella, G. Pennisi, J. Cai, W.M. Pierce, J.B. Klein, and D.A. Butterfield Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis Neurobiol. Aging 27 2006 1020 1034
38. D.A. Butterfield, and M.L. Lange Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism J. Neurochem. 111 2009 915 933
39. D.A. Butterfield, H.F. Poon St, D. Clair, J.N. Keller, W.M. Pierce, J.B. Klein, and W.R. Markesbery Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease Neurobiol. Dis. 22 2006 223 232
40. A. Castegna, M. Aksenov, V. Thongboonkerd, J.B. Klein, W.M. Pierce, R. Booze, W.R. Markesbery, and D.A. Butterfield Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71 J. Neurochem. 82 2002 1524 1532
41. M. Perluigi, H.F. Poon, W. Maragos, W.M. Pierce, J.B. Klein, V. Calabrese, C. Cini, C. De Marco, and D.A. Butterfield Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease Mol. Cell. Proteomics 4 2005 1849 1861
42. M.B. Schapiro, J.V. Haxby, C.L. Grady, R. Duara, N.L. Schlageter, B. White, A. Moore, M. Sundaram, S.M. Larson, and S.I. Rapoport Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome J. Neurol. Neurosurg. Psychiatry 50 1987 766 774
43. A. Dani, P. Pietrini, M.L. Furey, A.R. McIntosh, C.L. Grady, B. Horwitz, U. Freo, G.E. Alexander, and M.B. Schapiro Brain cognition and metabolism in Down syndrome adults in association with development of dementia Neuroreport 7 1996 2933 2936
44. M. Bajo, J. Fruehauf, S.H. Kim, M. Fountoulakis, and G. Lubec Proteomic evaluation of intermediary metabolism enzyme proteins in fetal Down's syndrome cerebral cortex Proteomics 2 2002 1539 1546
45. M.B. Schapiro, J.V. Haxby, and C.L. Grady Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology Neurobiol. Aging 13 1992 723 734
46. P. Bubber, V. Haroutunian, G. Fisch, J.P. Blass, and G.E. Gibson Mitochondrial abnormalities in Alzheimer brain: mechanistic implications Ann. Neurol. 57 2005 695 703
47. M.A. Korolainen, G. Goldsteins, T.A. Nyman, I. Alafuzoff, J. Koistinaho, and T. Pirttila Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain Neurobiol. Aging 27 2006 42 53
48. R. Sultana, T. Reed, M. Perluigi, R. Coccia, W.M. Pierce, and D.A. Butterfield Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study J. Cell. Mol. Med. 11 2007 839 851
49. T.T. Reed, W.M. Pierce, W.R. Markesbery, and D.A. Butterfield Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD Brain Res. 1274 2009 66 76
50. P.S. Hauser, V. Narayanaswami, R.O. Ryan, and E Apolipoprotein from lipid transport to neurobiology Prog. Lipid Res. 50 2011 62 74
51. D. Champagne, J.B. Dupuy, J. Rochford, and J. Poirier Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: analysis of learning strategies in three versions of the task Neuroscience 114 2002 641 654
52. M.S. Oitzl, M. Mulder, P.J. Lucassen, L.M. Havekes, J. Grootendorst, and E.R. de Kloet Severe learning deficits in apolipoprotein E-knockout mice in a water maze task Brain Res. 752 1997 189 196
53. C.M. Lauderback, J.M. Hackett, J.N. Keller, S. Varadarajan, L. Szweda, M. Kindy, W.R. Markesbery, and D.A. Butterfield Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer's disease Biochemistry 40 2001 2548 2554
54. T.A. Robertson, N.S. Dutton, R.N. Martins, A.D. Roses, B.A. Kakulas, and J.M. Papadimitriou Beta-amyloid protein-containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice Am. J. Pathol. 150 1997 417 427
55. E. Head, and I.T. Lott Down syndrome and beta-amyloid deposition Curr. Opin. Neurol. 17 2004 95 100
56. E. Weber, T. Jilling, and K.L. Kirk Distinct functional properties of Rab3A and Rab3B in PC12 neuroendocrine cells J. Biol. Chem. 271 1996 6963 6971
57. Reddy, P. H.; Mani, G.; Park, B. S.; Jacques, J.; Murdoch, G.; Whetsell, W., Jr.; Kaye, J.; Manczak, M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimer's Dis. 7:103-117; discussion 173-180; 2005.
58. J.S. Ju, R.A. Fuentealba, S.E. Miller, E. Jackson, D. Piwnica-Worms, R.H. Baloh, and C.C. Weihl Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease J. Cell Biol. 187 2009 875 888
59. D.J. Klionsky The molecular machinery of autophagy and its role in physiology and disease Semin. Cell Dev. Biol. 21 2010 663
60. T. Hara, K. Nakamura, M. Matsui, A. Yamamoto, Y. Nakahara, R. Suzuki-Migishima, M. Yokoyama, K. Mishima, I. Saito, H. Okano, and N. Mizushima Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice Nature 441 2006 885 889
61. M. Komatsu, S. Waguri, T. Chiba, S. Murata, J. Iwata, I. Tanida, T. Ueno, M. Koike, Y. Uchiyama, E. Kominami, and K. Tanaka Loss of autophagy in the central nervous system causes neurodegeneration in mice Nature 441 2006 880 884
62. R.A. Nixon Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases Neurobiol. Aging 26 2005 373 382
63. R.A. Nixon, and A.M. Cataldo Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease J. Alzheimer's Dis 9 2006 277 289
64. F. Di Domenico, R. Sultana, A. Ferree, K. Smith, E. Barone, M. Perluigi, R. Coccia, W. Pierce, J. Cai, C. Mancuso, R. Squillace, M. Wiengele, I. Dalle-Donne, B. Wolozin, and D.A. Butterfield Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease Antioxid. Redox Signaling 17 2012 1490 1506
65. Y. Jiang, K.A. Mullaney, C.M. Peterhoff, S. Che, S.D. Schmidt, A. Boyer-Boiteau, S.D. Ginsberg, A.M. Cataldo, P.M. Mathews, and R.A. Nixon Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition Proc. Natl. Acad. Sci. USA 107 2010 1630 1635
66. R.A. Nixon, and D.S. Yang Autophagy failure in Alzheimer's disease - locating the primary defect Neurobiol. Dis. 43 2011 38 45